£17.3m market cap
6.65p last close
Egdon Resources is an AIM-listed onshore oil and gas exploration company. The group has conventional and unconventional assets in the UK and access to over 188,000 net shale acres.
Investment summary
Basal Westphalian sandstones targeted at Biscathorpe-2 were found high to prognosis and poorly developed. Elevated gas readings and oil shows in the Dinantian Carbonate provide indication of an effective petroleum system and Egdon sees the potential for a better developed reservoir to the north and north-east of Biscathorpe-2, a potential target for a future side-track. Our last published conventional asset value for Egdon was 12.7p/share and included 3.6p/share of risked value for Biscathorpe-2, which we expect to remove. Valuation of Egdon’s net shale resource (188,000 net acres) remains uncertain but, in our view, has potential to be worth risked c 100p/share based on the current expectation of well cost, type curves and forward gas prices, assuming a supportive political and planning backdrop.
Y/E Jul |
Revenue (£m) |
EBITDA (£m) |
PBT (£m) |
EPS (fd) (p) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 1.0 | (1.2) | (2.2) | (0.7) | N/A | N/A |
| 2018A | 0.8 | (2.2) | (1.7) | (0.8) | N/A | N/A |
| 2019E | 3.2 | 0.1 | (0.6) | (0.2) | N/A | 27.2 |
| 2020E | 4.2 | (0.1) | (2.0) | (0.8) | N/A | 42.0 |
| Last updated on 21/02/2019 | ||||||
Industry outlook
The UK government’s stance towards shale varies by party. However, current central government appears to be supportive of unconventional gas development, attracting sector investment from the likes of Centrica and Ineos.
Last updated on 21/02/2019
Sector |
|---|
| Oil & gas |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (£m) | 0.9 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Philip Stephens | Chairman |
| Mark Abbott | MD |
